Comparative Clinical Outcomes for Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations

In patients with advanced NSCLC harboring exon 19 deletions or L858R substitution mutations in the epidermal growth factor receptor (EGFR) gene, treatment with EGFR tyrosine kinase inhibitors (TKIs) has demonstrated improvement in progression-free survival (PFS)[1 –5] and overall survival (OS)[6] compared with chemotherapy. These 2 mutation types, referred to here as common EGFR mutations (cEGFR), constitute approximately 80% to 90% of all EGFR mutations.[7–9] Clinical trials of the first-generation EGFR TKIs gefitinib and erlotinib [2,3,10–13] and seco nd-generation EGFR TKI afatinib [4–6] in patients with advanced NSCLC harboring cEGFR have shown a median PFS ranging from 8.0 to 13.6 months and a median OS ranging from 19.3 to 33.3 months.

Source: Lung Cancer - November 6, 2021 Category: Cancer & Oncology Authors: Lyudmila Bazhenova, Anna Minchom, Santiago Viteri, Joshua M. Bauml, Sai-Hong Ignatius Ou, Shirish M. Gadgeel, Jos é Manuel Trigo, Daniel Backenroth, Tracy Li, Anil Londhe, Parthiv Mahadevia, Nicolas Girard Source Type: research